Parsaclisib
CAS No. 1426698-88-5
Parsaclisib( INCB050465 )
Catalog No. M23581 CAS No. 1426698-88-5
Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 290 | In Stock |
|
| 10MG | 470 | In Stock |
|
| 25MG | 763 | In Stock |
|
| 50MG | 1053 | In Stock |
|
| 100MG | 1422 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameParsaclisib
-
NoteResearch use only, not for human use.
-
Brief DescriptionParsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
-
DescriptionParsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
-
In VitroParsaclisib (0.1-3000 nM; 4 d) inhibits proliferation of MCL and DLBCL cell lines.Parsaclisib (0.1-1000 nM; 2 h) inhibits anti-IgM-induced pAKT (Ser473) in the Ramos Burkitt’s lymphoma cell line, with an IC50 of 1 nM.Parsaclisib inhibits the proliferation of human, dog, rat, and mouse primary B cells after activation of these receptors, with IC50s ranging from 0.2 to 1.7 nM. Cell Proliferation Assay Cell Line:Jeko-1, Mino, JVM2, Rec-1, Pfeiffer, SU-DHL-5, SU-DHL-6, WSU-NHL, SU-DHL-4, SU-DHL-8, and WILL-2 cells Concentration:0.1-3000 nM Incubation Time:4 days Result:Resulted in a maximal inhibition of 70-90%, with IC50s of ≤10 nM in the four MCL cell lines.Pfeiffer, SU-DHL-5, SU-DHL-6, and WSU-NHL were highly sensitive, with IC50s from 2 to 8 nM.
-
In VivoParsaclisib (10 mg/kg; oral gavage twice daily for 7-19 days) inhibits tumor growth in the BALB/c mice bearing the A20 murine lymphoma cells.Parsaclisib (0.1-10 mg/kg; p.o. twice daily) slows Pfeiffer xenograft tumor growth in a dose-dependent manner. And Parsaclisib was well tolerated.Parsaclisib (0.5-1 mg/kg; a single p.o.) inhibits pAKT (Ser473) in Pfeiffer subcutaneous mouse xenograft models. Animal Model:Female BALB/c mice (5-9 weeks) were inoculated with A20 cells Dosage:10 mg/kg Administration:Oral gavage twice daily for 7-19 days Result:Resulted in significant tumor growth inhibition (TGI).Reduced the percentage of Tregs (CD4+CD25+FOXP3+) in tumors and spleens.Increased the ratio of CD4+ and CD8+ T cells to Tregs in spleens and tumors.Decreased the number of CD4+CD44high and CD8+CD44high T cells in both spleens and tumors.
-
SynonymsINCB050465
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3Kδ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1426698-88-5
-
Formula Weight432.88
-
Molecular FormulaC20H22ClFN6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:122 mg/mL?(281.83 mM;?Need ultrasonic)
-
SMILESCCOc(c([C@H](C)n1nc(C)c2c(N)ncnc12)c1)c([C@@H](C2)CNC2=O)c(F)c1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).
molnova catalog
related products
-
PI3K inhibitor X
PI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.
-
PIK-108
PIK-108 is an allosteric inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunits β and δ (PI3Kβ/δ).
-
LX-2343
LX-2343 is an non-ATP competitive PI3K inhibitor that negatively regulates AKT/mTOR signaling.
Cart
sales@molnova.com